Statistik Asas
| CIK | 1822462 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Foghorn Therapeutics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commis |
|
| September 2, 2025 |
a2025-09x02foghorncorpor September 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99. |
|
| August 5, 2025 |
investorpresentationdate August 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| August 5, 2025 |
Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors reinforces |
|
| July 1, 2025 |
Exhibit 10.2 1 15443181811 AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of June 27, 2025 (the “Effective Date”), by and between ARE-TECH SQUARE, LLC, a Delaware limited liability company (“Landlord”), and FOGHORN THERAPEUTICS INC., a Delaware corporat |
|
| July 1, 2025 |
Exhibit 10.1 15396256515 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 27th day of June, 2025 (the “Effective Date”), between ARE-MA REGION NO. 77, LLC, a Delaware limited liability company (“Landlord”), and FOGHORN THERAPEUTICS INC., a Delaware corporation (“Tenant”). BASIC LEASE PROVISIONS Building: 99 Coolidge Avenue, Watertown, Massachusetts Premises: That portion of the Bui |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2025 |
May 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99. |
|
| May 14, 2025 |
Exhibit 99.1 Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 5, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 1, 2025 |
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors Exhibit 99.1 Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) – May 1, 2025 - Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., a |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| April 28, 2025 |
April 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. |
|
| April 28, 2025 |
April 29, 2025 • Targeting SMARCA2-Dependent Tumors with FHD-909 (LY4050784) • Advancing Multiple Additional First-in-Class Anticancer Agents AACR April 2025 Exhibit 99. |
|
| April 28, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| April 28, 2025 |
Exhibit 99.3 Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-90 |
|
| March 24, 2025 |
March 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99. |
|
| March 24, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| March 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| March 20, 2025 |
As Filed Pursuant to 424(b)(5) Registration No. 333-284476 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2025) $100,000,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time through or to our sales agent, TD Securities (USA) LLC (as successor to Cowen and Company |
|
| March 20, 2025 |
, dated as of March 20, 2025, by and between Foghorn Therap Exhibit 1.1 FOGHORN THERAPEUTICS, INC. AMENDMENT NO. 1 TO COMMON STOCK SALES AGREEMENT March 20, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York 10017 Ladies and Gentlemen: Reference is made to the Common Stock Sales Agreement, dated April 15, 2022 (the “Agreement”), by and between Foghorn Therapeutics Inc., a Delaware corporation (the “Company”), and TD Securities (USA) LLC (“TD Cowen,” |
|
| March 6, 2025 |
Description of Registrant’s Securities Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of our common stock is qualified by reference to our amended and restated certificate of incorporation and bylaws, both of which are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.6 is a part. The summary below is also |
|
| March 6, 2025 |
Exhibit 99.1 Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinical combination data with pembrolizumab and KRAS inhibitors to be p |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 6, 2025 |
Foghorn Therapeutics Inc. Insider Trading Policy October 2023 Foghorn Therapeutics Inc. Insider Trading Policy 1.Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Foghorn Therapeutics Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which it does business. The Company’s Board of Directors (the “Board”) has adopted th |
|
| February 3, 2025 |
February 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99. |
|
| February 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| January 29, 2025 |
Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 January 29, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Foghorn Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-284476) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of t |
|
| January 24, 2025 |
As filed with the Securities and Exchange Commission on January 24, 2025 As filed with the Securities and Exchange Commission on January 24, 2025 Registration No. |
|
| January 24, 2025 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Foghorn Therapeutics Inc. |
|
| January 24, 2025 |
As filed with the Securities and Exchange Commission on January 24, 2025 As filed with the Securities and Exchange Commission on January 24, 2025 Registration No. |
|
| January 24, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| January 24, 2025 |
Calculation of Filing Fee Tables Calculation of Filing Fee Tables Form S-3 (Form Type) Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| January 13, 2025 |
Exhibit 99.1 Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population FHD-909 preclinical combination data with pembrolizumab and KRAS inhibitors to be presented |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| January 13, 2025 |
January 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99. |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commis |
|
| December 16, 2024 |
Exhibit 99.2 Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone Company to |
|
| December 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commis |
|
| December 16, 2024 |
December 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some |
|
| November 4, 2024 |
Exhibit 99.1 Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC Topline Phase 1 dose escalation data for FHD-286 plus decitabine in patients with relapsed and/or refractory AML expected by year-end 2 |
|
| November 4, 2024 |
Letter Agreement between Foghorn Therapeutics Inc. and Exhibit 10.1 July 18, 2024 Anna Rivkin 10 N. Main Street Stockton, NJ 08559 Dear Anna: This letter agreement (the “Agreement”) sets forth the terms and conditions of your employment with Foghorn Therapeutics Inc. (the “Company”). This Agreement will be effective as of July 18, 2024. 1. POSITION AND DUTIES Your position shall be Chief Business Officer. In this role, you will report to the Chief Exe |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| November 4, 2024 |
November 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.2 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some |
|
| October 10, 2024 |
Exhibit 99.2 Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2 oncology program is part of a U.S. |
|
| October 10, 2024 |
October 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| October 8, 2024 |
FHTX / Foghorn Therapeutics Inc. / Klarman Family Foundation Passive Investment SC 13G/A 1 s13ga100724-foghorn.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1) * Foghorn Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 344174107 (CUSI |
|
| September 20, 2024 |
FHTX / Foghorn Therapeutics Inc. / Flynn James E Passive Investment SC 13G 1 e663901sc13g-foghorn.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Foghorn Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 344174107 (CUSIP Number) September |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2024 |
August 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.2 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some c |
|
| August 8, 2024 |
Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024 Dosing of first patient in a Phase 1 trial for FHD-909, a potential first-in-class SMARCA2 selective inhibitor, anticipated in the second h |
|
| August 8, 2024 |
424B5 Table of Contents As Filed Pursuant to 424(b)(5) Registration No. 333-262711 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 14, 2022) $190,000,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock having an aggregate offering price of up to $190,000,000 from time to time through or to our sales agent, Cowen and Company, LLC, or TD Cowen, |
|
| June 26, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2024 |
June 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some cas |
|
| May 30, 2024 |
SC 13G 1 sc13g07422fog05302024.htm THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Foghorn Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (T |
|
| May 30, 2024 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated May 30, 2024 with respect to the Common Stock, $0.0001 par value per share, of Foghorn Therapeutics Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance wit |
|
| May 24, 2024 |
FHTX / Foghorn Therapeutics Inc. / Flagship Ventures Fund V, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* FOGHORN THERAPEUTICS INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 344174 10 7 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Nam |
|
| May 23, 2024 |
May 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some case |
|
| May 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2024 |
Exhibit 4.1 FOGHORN THERAPEUTICS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: May [•], 2024 Foghorn Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted reg |
|
| May 22, 2024 |
Exhibit 1.1 12,743,039 Shares of Common Stock Pre-Funded Warrants to Purchase 7,220,794 Shares of Common Stock Foghorn Therapeutics Inc. UNDERWRITING AGREEMENT May 20, 2024 JEFFERIES LLC TD SECURITIES (USA) LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, |
|
| May 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 20, 2024 |
May 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some case |
|
| May 20, 2024 |
12,743,039 Shares of Common Stock Pre-Funded Warrants to Purchase 7,220,794 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-262711 PROSPECTUS SUPPLEMENT (To Prospectus dated March 14, 2022) 12,743,039 Shares of Common Stock Pre-Funded Warrants to Purchase 7,220,794 Shares of Common Stock We are offering 12,743,039 shares of our common stock. We are also offering in lieu of the shares of our common stock to certain investors, pre-funded warrants t |
|
| May 6, 2024 |
Exhibit 99.1 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) selective inhibitor; P |
|
| May 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Foghorn Therapeutics Inc. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| May 6, 2024 |
As filed with the Securities and Exchange Commission on May 6, 2024 As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2024 |
May 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some case |
|
| May 3, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| April 16, 2024 |
Exhibit 99.1 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) – April 16, 2024 - Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian |
|
| April 16, 2024 |
Letter Agreement between Foghorn Therapeutics Inc. Exhibit 10.1 April 12, 2024 Kristian F. Humer 155 West 11th Street #4G New York, NY 10011 Dear Kristian: This letter agreement (the “Agreement”) sets forth the terms and conditions of your employment with Foghorn Therapeutics Inc. (the “Company”). This Agreement will be effective as of April 16, 2024. 1. POSITION AND DUTIES Your position shall be Chief Financial Officer. In this role, you will rep |
|
| April 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| April 9, 2024 |
Exhibit 99.3 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust |
|
| April 9, 2024 |
April 9, 2024 Unique biology Precision therapeutics Broad impact 2024 AACR and Pipeline Update Exhibit 99. |
|
| April 9, 2024 |
April 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.2 | Forward Looking Statements 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “could,” “may,” “might,” “will,” “likely,” |
|
| March 7, 2024 |
Therapeutics Inc. Policy for Recoupment of Incentive Compensation September 2023 FOGHORN THERAPEUTICS INC. POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1.Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of Foghorn Therapeutics Inc. (the “Company”) has adopted a policy (the “Policy”) providing for the Company’s recoupment of certain incentive-bas |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2024 |
fhtxcorpdeckxmar2024xfi March 2024 Unique biology Precision therapeutics Broad impact Exhibit 99. |
|
| March 7, 2024 |
Exhibit 99.1 Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook •Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 •FHD-909, a first-in-class BRM selective inhibitor, selected for clinical development by partner Lilly; preclinical data to be presented at AACR with IND planned for the secon |
|
| March 7, 2024 |
Consulting Agreement between Foghorn Therapeutics Inc. and Ian F. Smith, dated as of CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of the 8th day of December, 2023(the “Effective Date”), by and between Foghorn Therapeutics Inc. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| February 8, 2024 |
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor Exhibit 99.2 Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) – February 8, 2024 - Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Lilly has selected FHD-909, a first-in-class oral BRM s |
|
| February 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| February 8, 2024 |
February 2024 Unique biology Precision therapeutics Broad impact Exhibit 99.1 | Forward Looking Statements 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “could,” “may,” “might,” “will,” “likely |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| January 8, 2024 |
Exhibit 99.1 Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 -FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs) in EGFR/KRAS resistance anticipated by the second quarter of 2024 |
|
| January 8, 2024 |
exhibit992investorpresen January 2024 Unique biology Precision therapeutics Broad impact Exhibit 99. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| January 3, 2024 |
Foghorn Therapeutics Announces CFO Departure Exhibit 99.1 Foghorn Therapeutics Announces CFO Departure CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) – January 03, 2024 - Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue a |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commis |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| November 2, 2023 |
Exhibit 99.1 Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update –First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024 –Transitioned the BRM Selective inhibitor program to Loxo@Lilly –Presented preclinical data demonstrating tumor growth inhibition and favorable safety profiles for Selective EP300 and Selective CBP programs – |
|
| November 2, 2023 |
Agreement between Foghorn Therapeutics Inc. and Exhibit 10.1 Execution Version August 4, 2023 Alfonso Quintás Cardama, M.D. 36 Pine Crest Road Newton Centre, MA 02459 Dear Alfonso: This letter agreement (the “Agreement”) sets forth the terms and conditions ofyour employment with Foghorn Therapeutics Inc. (the “Company”). This Agreement will be effective as of August 7, 2023. 1.POSITION AND DUTIES Your position shall be Chief Medical Officer. In |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| November 2, 2023 |
CORPORATE OVERVIEW November 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commis |
|
| September 8, 2023 |
CORPORATE OVERVIEW September 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| August 31, 2023 |
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML CAMBRIDGE, Mass. |
|
| August 31, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2023 |
Foghorn Therapeutics Announces Chief Medical Officer Succession Exhibit 99.1 Foghorn Therapeutics Announces Chief Medical Officer Succession CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) - August 8, 2023 - Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| August 4, 2023 |
Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update –Initiating FHD-286 combination study in AML in the third quarter of 2023 –Selective BRM, ARID1B, EP300, and CBP, targeting key regulators of gene expression, continue to advance toward IND –Cash, cash equivalents, and marketable securities of $284.3 million, as of June 30, 2023, provides cash runway into |
|
| August 4, 2023 |
ex992fhtxcorpdeckxaug20 CORPORATE OVERVIEW August 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2023 |
Exhibit 99.2 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma -Clinical data support safety and tolerability profile of FHD-286, a highly potent, selective, allosteric, oral, small molecule inhibitor of BRG1/BRM -Clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a |
|
| June 28, 2023 |
ex991-fhtxcorporatedeck CORPORATE OVERVIEW June 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 5, 2023 |
fhtxcorpdeckxjune2023 CORPORATE OVERVIEW June 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| June 5, 2023 |
Exhibit 99.2 Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients -Plan to Initiate a Phase 1 Study of FHD-286 in Combination with Decitabine or Cytarabine in Relapsed and/or Refractory AML Patients in Q3’2023 -Clinical and Pre-Clinical Data Suggest FHD-286 Has the Potential to Be a First-in-Class Broad-Based Differe |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2023 |
Exhibit 99.1 Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update –Data from Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma expected in the second quarter of 2023 –Selective BRM, ARID1B, EP300 and CBP, targeting key regulators of gene expression, continue to advance towards IND –Cash, cash equivalents and marketable securitie |
|
| May 8, 2023 |
ex992fhtxcorpdeckxmay20 CORPORATE OVERVIEW May 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| May 8, 2023 |
Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Foghorn Therapeutics |
|
| May 8, 2023 |
As filed with the Securities and Exchange Commission on May 8, 2023 S-8 1 s-82023evergreensharesxfeb.htm S-8 As filed with the Securities and Exchange Commission on May 8, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOGHORN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 47-5271393 (State or other jurisdiction of i |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission F |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2023 |
DEFA14A 1 d420657ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 24, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| April 24, 2023 |
Foghorn Therapeutics Provides an Update on FHD-609 Exhibit 99.1 Foghorn Therapeutics Provides an Update on FHD-609 CAMBRIDGE, Mass.-(GLOBE NEWSWIRE)-April 24, 2023-Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced an update on the FHD-609 program in synovial sarcoma and SMARCB1-deleted tumors. Fogh |
|
| March 9, 2023 |
Exhibit 3.1 FOGHORN THERAPEUTICS INC. AMENDED AND RESTATED BYLAWS, As amended and restated March 7, 2023 SECTION 1 -STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of Foghorn Therapeutics Inc., a Delaware corporation (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly c |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2023 |
Exhibit 99.1 Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update - Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to progress wi |
|
| March 9, 2023 |
fhtxcorpdeckxmarch92023 CORPORATE OVERVIEW March 9, 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| March 8, 2023 |
fhtxcorpdeckxmarch82023 CORPORATE OVERVIEW March 8, 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| January 9, 2023 |
CORPORATE OVERVIEW January 2023 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| January 9, 2023 |
Exhibit 99.1 Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023 - Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovia |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| November 8, 2022 |
CORPORATE OVERVIEW November 2022 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| November 8, 2022 |
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update Exhibit 99.1 Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update ?FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023 ?FHD-609 Phase 1 pharmacodynamic data shows degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies; initial Phase 1 dose escalation efficacy |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| October 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| October 26, 2022 |
Exhibit 99.1 Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program Initial Phase 1 data of FHD-609 show degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies New preclinical data demonstrate FHD-609 is highly selective, with no off-target IMiD neosubstrate degradation activity Newly announce |
|
| October 26, 2022 |
CORPORATE OVERVIEW October 2022 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| August 31, 2022 |
Foghorn Therapeutics Announces Change to Board of Directors ?Foghorn Congratulates Co-Founder Cigall Kadoch on HHMI Appointment and Change in Role to Scientific Advisor to the Board CAMBRIDGE, Mass. |
|
| August 23, 2022 |
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS Exhibit 99.1 Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) ? August 23, 2022 - Foghorn? Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced tha |
|
| August 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| August 23, 2022 |
CORPORATE OVERVIEW August 2022 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| August 9, 2022 |
Exhibit 10.2 Promoted Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the ?Agreement?) I, the undersigned, in consideration for and as a condition of my proposed promotion and continued employment by Foghorn Therapeutics, Inc. (the ?Company?) and other good and valuable consideration (including, without limitation, the covenant to make the payments described i |
|
| August 9, 2022 |
Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update –FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS –On track to report initial Phase 1 clinical data for FHD-609 in synovial sarcoma in 2023 –Research milestone achieved under Merck collaboration i |
|
| August 9, 2022 |
Exhibit 10.1 July 15, 2022 Carlos Costa By Email Delivery Dear Carlos: This letter agreement (this ?Agreement?) amends and restates the offer letter dated October 14, 2020 (the ?Offer Letter?) by and between you and Foghorn Therapeutics Inc. (the ?Company?). This Agreement sets forth the terms and conditions of your continued employment with the Company. This Agreement will be effective as of Augu |
|
| August 9, 2022 |
CORPORATE OVERVIEW August 2022 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| July 28, 2022 |
Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 CORRESP 1 filename1.htm Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 July 28, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tara Harkins, Daniel Gordon, Office of Life Sciences Re: Foghorn Therapeutics Inc. Form 10-K for the Fiscal Year ended December 31, 2021 Filed March 10, |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 8, 2022 |
CORPORATE OVERVIEW June 2022 Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond Exhibit 99. |
|
| June 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 19, 2022 |
Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases May 2022 Exhibit 99. |
|
| May 19, 2022 |
Exhibit 99.2 Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS CAMBRIDGE, Mass. - (GLOBE NEWSWIRE) - May 19, 2022 - Foghorn? Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced |
|
| May 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2022 |
Exhibit 99.1 Foghorn Therapeutics Provides First Quarter 2022 Corporate Update ?Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial clinical data expected for FHD-286 in H2 2022 and FHD-609 in 2023 ?New preclinical data for FHD-286 presented at AACR prov |
|
| May 9, 2022 |
Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases May 2022 Exhibit 99. |
|
| May 9, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this "First Amendment") is made as of this 29th day of June, 2020, by and between ARE-TECH SQUARE, LLC, a Delaware limited liability company ("Landlord"), and FOGHORN THERAPEUTICS INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of October 23, 2019 ( |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission F |
|
| April 29, 2022 |
DEFA14A 1 d307415ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 15, 2022 |
, 2022, by and between Foghorn Therapeutics Inc. and Cowen and Company, LLC Exhibit 1.1 FOGHORN THERAPEUTICS INC. $200,000,000 COMMON STOCK SALES AGREEMENT April 15, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Foghorn Therapeutics Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during th |
|
| April 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2022 Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39634 47-5271393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 15, 2022 |
Table of Contents As Filed Pursuant to 424(b)(5) Registration No. 333-262711 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 14, 2022) $200,000,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock having an aggregate offering price of up to $200,000,000 from time to time through or to our sales agent, Cowen and Company, LLC, or Cowen, as sa |
|
| April 15, 2022 |
As filed with the Securities and Exchange Commission on April 15, 2022 As filed with the Securities and Exchange Commission on April 15, 2022 Registration No. |
|
| March 10, 2022 |
Exhibit 10.24 January 27, 2022 Fanny Cavalie By Email Delivery Dear Fanny: This letter agreement (the ?Agreement?) amends and restates the offer letter dated October 14, 2020 (the ?Offer Letter?) by and among you and Foghorn Therapeutics Inc. (the ?Company?). This Agreement sets forth the terms and conditions of your continued employment with the Company. This Agreement will be effective as of the |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 10, 2022 |
Exhibit 99.1 Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook ?Initial clinical data for FHD-286 expected in H1?22 and FHD-609 as early as H1?22 ?Advancing broad therapeutic pipeline of oncology programs including protein degraders, enzymatic inhibitors and transcription factor disruptors ?Entered strategic collaboration in December 2021 with Loxo Oncology at Lilly fo |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| March 10, 2022 |
Exhibit 10.27 Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement In consideration and as a condition of my employment or continued employment by Foghorn Therapeutics, Inc. (the ?Company?) and other good and valuable consideration (including, without limitation, the payments described in Section 8 below), I, the undersigned of this Employee Non-Competition, Non-Sol |
|
| March 10, 2022 |
Letter Agreement between Foghorn Therapeutics Inc. and Carl Decicco, dated January 10, 2022. Exhibit 10.26 January 10, 2022 Carl Decicco By Email Delivery Dear Carl: This letter agreement (this ?Agreement?) confirms the terms of the remainder of your employment with Foghorn Therapeutics Inc. (together with its subsidiary, the ?Company?) and certain benefits to be provided to you by the Company. We agree as follows: Transition Period. Transition. Subject to earlier termination as provided |
|
| March 10, 2022 |
Exhibit 10.22 October 14, 2020 Allan Reine By Email Delivery Dear Allan: Execution Version This letter agreement (the ?Agreement?) amends and restates the offer letter dated July 23, 2019, as amended August 29, 2019 (the ?Offer Letter?), by and among you and Foghorn Therapeutics Inc. (the ?Company?). This Agreement sets forth the terms and conditions of your continued employment with the Company. |
|
| March 10, 2022 |
FOGHORN THERAPEUTICS INC. 500 Technology Square, Ste 700 Cambridge, MA 02139 FOGHORN THERAPEUTICS INC. 500 Technology Square, Ste 700 Cambridge, MA 02139 March 10, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz, Division of Corporation Finance, Office of Life Sciences Re: Foghorn Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-262711) Request for Accelerat |
|
| March 10, 2022 |
Ex 10.21 CERTAIN INFORMATION IDENTIFIED WITH [***] IN THIS EXHIBIT HAS BEEN OMITTED BECAUSE THE REGISTRANT HAS DETERMINED THAT THEY ARE NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. COLLABORATION AGREEMENT between ELI LILLY AND COMPANY and FOGHORN THERAPEUTICS INC. CONFIDENTIAL TABLE OF CONTENTS Article 1 DEFINITIONS 2 Article 2 GOVERNANCE AND JOINT |
|
| March 10, 2022 |
EX-10.23 4 ex1023-employmentagreement.htm EX-10.23 Exhibit 10.23 January 26, 2022 Steve Bellon, Ph.D. By Email Delivery Dear Steve: This letter agreement (the “Agreement”) amends and restates the offer letter dated April 27, 2016 (the “Offer Letter”) by and among you and Foghorn Therapeutics Inc. (the “Company”). This Agreement sets forth the terms and conditions of your continued employment with |
|
| March 10, 2022 |
Exhibit 10.25 October 29, 2020 Michael LaCascia By Email Delivery Dear Mike: This letter agreement (the ?Agreement?) amends and restates the offer letter dated September 11, 2020 (the ?Offer Letter?) by and among you and Foghorn Therapeutics Inc. (the ?Company?). This Agreement sets forth the terms and conditions of your employment with the Company. This Agreement will be effective as of the date |
|
| February 14, 2022 |
As filed with the Securities and Exchange Commission on February 14, 2022 As filed with the Securities and Exchange Commission on February 14, 2022 Registration No. |
|
| February 14, 2022 |
Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Foghorn Therapeutics |
|
| February 14, 2022 |
As filed with the Securities and Exchange Commission on February 14, 2022 S-3 1 s-3.htm S-3 As filed with the Securities and Exchange Commission on February 14, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOGHORN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizati |
|
| February 14, 2022 |
Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39634 47-5271393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 21, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2021 Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39634 47-5271393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 13, 2021 |
FHTX / Foghorn Therapeutics Inc. / ELI LILLY & Co - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Foghorn Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 344174107 (CUSIP Number) December 10, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2021 Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39634 47-5271393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 13, 2021 |
EX-4.1 2 ex41amendmenttoira.htm EX-4.1 Exhibit 4.1 Foghorn Therapeutics Inc. Amendment to Amended and Restated Investors’ Rights Agreement This Amendment (this “Amendment”) is made as of December 10, 2021, by and among Foghorn Therapeutics Inc., a Delaware corporation (the “Corporation”), and the Investors set forth on the signature pages hereto and amends that certain Amended and Restated Investo |
|
| December 13, 2021 |
Stock Purchase Agreement, dated as of December 10, 2021, EX-10.1 3 ex101stockpurchaseagreement.htm EX-10.1 Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (“Agreement”) is entered into as of December 10, 2021 (the “Execution Date”), by and between Foghorn Therapeutics Inc., a Delaware corporation (“Foghorn”), and Eli Lilly and Company, an Indiana corporation (“Lilly”). Foghorn and Lilly may individually be referred to as a “Party” an |
|
| December 13, 2021 |
EX-99.2 5 ex992foghorninvestorpres.htm EX-99.2 Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases December 2021 Exhibit 99.2 Disclaimer, Confidentiality, and Forward-Looking StatementsThis presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are f |
|
| December 13, 2021 |
EX-99.1 4 ex991collaborationpressrel.htm EX-99.1 Exhibit 99.1 Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform –Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program –Collaboration includes three additional discovery programs –Fogh |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2021 |
EX-99.1 2 ex99111921.htm EX-99.1 Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update - First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma - Continue to enroll patients in phase 1 clinical trials of FHD-286, an inhibitor of BRG1/BRM, in metastatic |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| September 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| September 1, 2021 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of August 30, 2021 (the “Second Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such |
|
| August 23, 2021 |
EX-99.1 2 ex991fhd-609fpipressrelease.htm EX-99.1 Foghorn Therapeutics Announces First Patient Dosed in First-in- Human Clinical Trial of FHD-609 FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9 Foghorn’s first protein degrader program to enter the clinic; continues pre-clinical work on other protein degrader programs for broad range of cancers Significant unmet ne |
|
| August 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| August 10, 2021 |
Exhibit 10.1 Execution Version CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) is made effective as of the 23rd day of June, 2021 (the ?Effective Date?), by and between Foghorn Therapeutics Inc., a Delaware corporation with principal offices at 500 Technology Square, Suite 700, Cambridge, MA 02139 (?Company?), and Ian F. Smith, an individual residing at 45 Commonwealth Ave, Unit 3 |
|
| August 10, 2021 |
EX-99.1 2 ex991.htm EX-99.1 Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) - IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated - Continued Advancement of Broad Therape |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissi |
|
| July 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| July 14, 2021 |
Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases July 2021 Disclaimer, Confidentiality, and Forward-Looking StatementsThis presentation contains forward-looking statements. |
|
| July 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 15, 2021 |
9:00 -9:10 a.m. 9:10 -9:25 a.m. 9:25 -9:45 a.m. 9:45 -10:05 a.m. 10:05 -10:20 a.m. 10:20 -10:30 a.m. 10:30 -10:45 a.m. 10:45 -11 :00 a.m. FOGHORN' THlaRAPlaVTICS Welcome and Introduction Adrian Gottschalk, P resident and CEO, Foghorn Therapeutics Chromatin Regulatory System -Disease Relevance Cigall Kadoch, Ph.D., Broad Institute, DFCI, Scientific Co-founder Foghorn Therapeutics Gene Traffic Contr |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 15, 2021 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of June 14, 2021 (the ?First Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral a |
|
| June 1, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| June 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commission |
|
| June 1, 2021 |
EX-99.1 2 finaljune2021foghorninve.htm EX-99.1 Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases June 2021 Disclaimer, Confidentiality, and Forward-Looking StatementsThis presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking st |
|
| May 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| April 19, 2021 |
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* FOGHORN THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 344174107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| March 18, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 18, 2021 |
Exhibit 10.18 Execution Version October 29, 2020 Cigall Kadoch, Ph.D. By Email Delivery Dear Dr. Kadoch: Reference is made to that certain letter agreement dated October 1, 2015, by and between you and Foghorn Therapeutics Inc. (the ?Company?), as amended by that certain fee increase letter dated January 22, 2019 (such agreement, as so amended, the ?Consulting Agreement?). The purpose of this lett |
|
| March 18, 2021 |
Description of Registrant’s Securities Exhibit 4.6 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes all material provisions of the common stock, par value $0.0001 per share, of Foghorn Therapeutics Inc. The description of our common stock is qualified by reference to our certificate of incorporation, bylaws, and investor rights agreement, |
|
| March 18, 2021 |
EX-99.1 2 d124191dex991.htm EX-99.1 Exhibit 99.1 Foghorn Therapeutics Provides Corporate Update - FHD-286 Phase 1 data anticipated as early as year-end 2021 - FHD-609 IND submission on track for the second quarter 2021 - Continued advancement of broad therapeutic pipeline targeting the chromatin regulatory system CAMBRIDGE, Mass.—(GLOBAL NEWSWIRE)— March 18, 2021—Foghorn Therapeutics Inc. (Nasdaq: |
|
| March 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commissio |
|
| February 16, 2021 |
Exhibit 99.1 Targeting the Chromatin Regulatory System A Product Platform with Potential to Impact Millions of Patients February 16, 2021Exhibit 99.1 Targeting the Chromatin Regulatory System A Product Platform with Potential to Impact Millions of Patients February 16, 2021 Precision Oncology: Novel Biology with Breadth and Depth Large Market Potential / Precision Approach Experienced Leadership T |
|
| February 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Commis |
|
| February 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. ) * Foghorn Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 344174107 (CUSIP Number) December 31, 2020 (Date of |
|
| January 15, 2021 |
S-8 As filed with the Securities and Exchange Commission on January 15, 2021 Registration No. |
|
| December 4, 2020 |
EX-99.1 Exhibit 99.1 Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration - On track to submit an IND for FHD-286 by year end 2020 and for FHD-609 during the first half of 2021 - Strengthened management team with the appointment of Michael LaCascia as Chief |
|
| December 4, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39634 Foghorn Therapeutics Inc. |
|
| December 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-39634 47-5271393 (State or other jurisdiction of incorporation) (Com |
